John Overdeck’s Alpine Immune Sciences Inc ALPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-519,971
| Closed | -$20.6M | – | 3442 |
|
|
2024
Q1 | $20.6M | Buy |
519,971
+141,558
| +37% | +$4.18M | 0.05% | 435 |
|
|
2023
Q4 | $7.21M | Buy |
378,413
+187,824
| +99% | +$2.61M | 0.02% | 817 |
|
|
2023
Q3 | $2.18M | Buy |
190,589
+132,561
| +228% | +$1.63M | 0.01% | 1323 |
|
|
2023
Q2 | $597K | Buy |
+58,028
| New | +$523K | ﹤0.01% | 2249 |
|
|
2022
Q4 | – | Sell |
-21,924
| Closed | -$158K | – | 3144 |
|
|
2022
Q3 | $158K | Buy |
21,924
+1,894
| +9% | +$15.6K | ﹤0.01% | 2157 |
|
|
2022
Q2 | $170K | Sell |
20,030
-27,678
| -58% | -$239K | ﹤0.01% | 2192 |
|
|
2022
Q1 | $428K | Sell |
47,708
-31,974
| -40% | -$276K | ﹤0.01% | 2092 |
|
|
2021
Q4 | $1.1M | Buy |
79,682
+40,464
| +103% | +$501K | ﹤0.01% | 2462 |
|
|
2021
Q3 | $418K | Buy |
39,218
+22,304
| +132% | +$206K | ﹤0.01% | 3405 |
|
|
2021
Q2 | $152K | Sell |
16,914
-90,467
| -84% | -$983K | ﹤0.01% | 3845 |
|
|
2021
Q1 | $1.14M | Sell |
107,381
-41,062
| -28% | -$512K | ﹤0.01% | 2193 |
|
|
2020
Q4 | $1.87M | Buy |
148,443
+67,078
| +82% | +$658K | 0.01% | 1537 |
|
|
2020
Q3 | $715K | Buy |
81,365
+3,066
| +4% | +$28K | ﹤0.01% | 1985 |
|
|
2020
Q2 | $760K | Buy |
+78,299
| New | +$339K | ﹤0.01% | 1713 |
|
John Overdeck's ALPN Position: Q2 2024 in Review
John Overdeck sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 519,971 shares — an estimated $20.6M sold.
John Overdeck first reported a position in ALPN in Q2 2020 and held it in 14 quarters. The position peaked at $20.6M in Q1 2024. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.
- John Overdeck reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
- John Overdeck sold 519,971 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $20.6M.
- John Overdeck first reported a position in Alpine Immune Sciences Inc in Q2 2020 and held it in 14 quarters.
- John Overdeck's Alpine Immune Sciences Inc position peaked at $20.6M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.
Based on Two Sigma Investments's 13F filing for Q2 2024, filed 14 Aug 2024.